The latest news & stories from the Providence Research Network

Providence Cancer Institute leader joined experts in cancer research, policy and advocacy to discuss current challenges and the future of research.

A medication designed to block and break down the androgen receptor, a key driver of prostate cancer growth, is being evaluated in a clinical trial at Providence Cancer Institute.

In a paper published in the prestigious New England Journal of Medicine AI, researchers from Providence and Microsoft propose an AI framework that could accelerate biomedical discovery.

Two new trials evaluating new medications or combinations of medications for people with ovarian cancer or small cell lung cancer open at Providence Cancer Institute.

In a new study led by the Providence Swedish Cancer Institute’s Kelly Paulson, M.D., Ph.D., survival rates more than doubled for a group treated with a novel, two-drug combination. Learn more.

A recently published Providence Research Network study found that patient-provider communication, unmet social needs, and other factors can influence whether patients adhere to their ASCVD treatments.

An interview with Providence researchers for the news website Healthcare Intelligence looks at findings from a recent study on the impact of an AI solution on provider documentation burden and burnout

When metastatic breast cancer rocked Renee Leaf's world, she found strength in her life's treasures and a Providence Swedish care team determined to save her life. Watch the video and learn more.

A new medication developed at Providence Cancer Institute is being evaluated in a clinical trial for people with advanced cancers.

In a Providence study published last week in the Future Healthcare Journal, physicians reported significant reductions in burnout when using DAX Copilot.

Research and an environmental scan by the Center for Outcomes Research & Education (CORE) offer key lessons for healthcare leaders working to advance Pharmacogenetic screenings in healthcare settings.

A phase III clinical trial for people with HR+ HER2- breast cancer aims to extend survival and improve patients’ quality of life.

Published in Nature NPJ Genomic Medicine, Providence-led Geno4ME research program study highlights early detection, personalized prevention and prospect of improved care outcomes.

Recognizing the links between housing and health, Medicaid programs are testing new housing benefit programs. Research by Providence CORE published in JAMA offers valuable insights for these efforts.

For decades, brain cancer has remained one of the most difficult forms of cancer to treat. A new wave of research and advances in personalized treatments are bringing new hope.

Expert voices in immuno-oncology from inside and outside Providence gather for a day of thought-provoking discussion, discovery and collaboration.

Explore new findings in cancer immunotherapy and clinical research from Providence at ASCO 2025.

Providence documented and tracked more than 8,500 goals of care conversations in its electronic health record for critical care patients in 2024.

Providence Cancer Institute is enrolling patients for two new immunotherapy trials targeting muscle-invasive urothelial cancer and advanced solid tumors.